JWH-185

	JWH-185 JWH-185 is a synthetic cannabinoid receptor ligand from the naphthoylindole family. It is the carbonyl-reduced derivative of related compound JWH-081. The binding affinity of JWH-185 for the CB1 receptor is reported as Ki = 17 ± 3 nM. In the United States, all CB1 receptor agonists of the 3-(1-naphthylmethane)indole class such as JWH-185 are Schedule I Controlled Substances. See also * JWH-081 * JWH-184 References JWH cannabinoids Naphthoylindoles CB1 receptor agonists {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	JWH Cannabinoids The John W. Huffman research group at Clemson University synthesized over 450 cannabinoids. Some of those are: [Baidu]
	JWH-184 JWH-184 is a synthetic cannabinoid receptor ligand from the naphthylmethylindole family. It is the carbonyl-reduced derivative of related compound JWH-122. The binding affinity of JWH-184 for the CB1 receptor is reported as Ki = 23 ± 6 nM. In the United States, all CB1 receptor agonists of the 3-(1-naphthylmethane)indole class such as JWH-184 are Schedule I Controlled Substances. See also * JWH-018 * JWH-122 * JWH-185 References JWH cannabinoids CB1 receptor agonists Naphthalenes Indoles {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	Cannabinoid Receptor Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system a class of cell membrane receptors in the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cannabinoid receptors contain seven transmembrane spanning domains. Cannabinoid receptors are activated by three major groups of ligands: endocannabinoids; plant cannabinoids (such as Tetrahydrocannabinol, produced by the cannabis plant); and synthetic cannabinoids (such as HU-210). All of the endocannabinoids and phytocannabinoids (plant based cannabinoids) are lipophilic. There are two known subtypes of cannabinoid receptors, termed CB1 and CB2. The CB1 receptor is expressed mainly in the brain (central nervous system or "CNS"), but also in the lungs, liver and kidneys. The CB2 receptor is expressed mainly in the immune system, in hematopoietic cells, and in parts of the brain. The protein sequences of CB1 and CB2 receptors are about 44% similar. When ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
picture info	Naphthoylindole Naphthoylindoles are a class of synthetic cannabinoids. See also * Structural scheduling of synthetic cannabinoids To combat the illicit synthetic cannabinoid industry many jurisdictions have created a system to control these cannabinoids through their general (or Markush) structure as opposed to their specific identity. In this way new analogs are already cont ... References {{reflist ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	JWH-081 JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. With a Ki of 1.2nM it is fairly selective for the CB1 subtype, its affinity at this subtype is measured at approximately 10x the affinity at CB2(12.4nM). It was discovered by and named after John W. Huffman. JWH-081 may be neurotoxic to animals when administered in high doses. Legal status In the United States, JWH-081 is a Schedule I Controlled Substance. As of October 2015, JWH-081 is a controlled substance in China. See also JWH-018 JWH-098 JWH-164 JWH-198 JWH-210 JWH-210 is an analgesic chemical from the naphthoylindole family, which acts as a potent cannabinoid agonist at both the CB1 and CB2 receptors, with Ki values of 0.46 nM at CB1 and 0.69 nM at CB2. It is one of the most potent 4-substi ... References Designer drugs JWH cannabinoids Naphthoylindoles Phenol ethers CB1 receptor agonists {{canna ... [...More Info...] [...Related Items...] OR:* [Wikipedia] [Google] [Baidu]
	Schedule I Controlled Substance This is the list of Schedule I drugs as defined by the United States Controlled Substances Act. 21 CFRbr>1308.11(CSA Sched I) with changes through (Oct 18, 2012). Retrieved September 6, 2013. The following findings are required for drugs to be placed in this schedule: # The drug or other substance has a high potential for abuse. # The drug or other substance has no currently accepted medical use in treatment in the United States. # There is a lack of accepted safety for use of the drug or other substance under medical supervision. Except as specifically authorized, it is illegal for any person: # to manufacture, distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance; or # to create, distribute, dispense, or possess with intent to distribute or dispense, a counterfeit substance. Additional substances are added to the list by the Secretary of Health and Human Services pursuant to 21 CFR 1308.49. [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Naphthoylindoles Naphthoylindoles are a class of synthetic cannabinoids. See also * Structural scheduling of synthetic cannabinoids To combat the illicit synthetic cannabinoid industry many jurisdictions have created a system to control these cannabinoids through their general (or Markush) structure as opposed to their specific identity. In this way new analogs are already cont ... References {{reflist ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]